XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease with secondary programs focused on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.


Media and Videos

Scroll with arrows for additional content


Press Releases

XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)

● TMX-049 Results Show Beneficial Decrease of Urinary Albumin in T2DN ● CALGARY, AB – September 19, 2019 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is pleased to share, in conjunction with ...
Read More

Receive Press Releases by email

Please enable the javascript to submit this form

Investor Relations

Fact Sheet

Presentation

Read More